M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Recruiting

Conditions: Recurrent Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Blasts 20 Percent or More of Bone Marrow Nucleated Cells
Refractory Acute Myeloid Leukemia
Refractory High Risk Myelodysplastic Syndrome
High Risk Myelodysplastic Syndrome
Recurrent High Risk Myelodysplastic Syndrome

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Idarubicin
Drug: Quizartinib

First Posted Date: 2019-08-07

Last Posted Date: 2024-12-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04047641

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Phase 1

Recruiting

Conditions: Breast Cancer
Melanoma
Uterine Cancer
Colitis
Diarrhea
Ovarian Cancer
Cervical Cancer
Malignant Genitourinary System Neoplasm
Lung Cancer

Interventions: Procedure: Fecal Microbiota Transplantation
Drug: Loperamide

First Posted Date: 2019-07-31

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04038619

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Phase 2

Active, not recruiting

Conditions: Stage II Laryngeal Cancer AJCC v8
Stage III Laryngeal Cancer AJCC v8
Laryngeal Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Docetaxel
Biological: Pembrolizumab

First Posted Date: 2019-07-24

Last Posted Date: 2024-07-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT04030455

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery

Phase 3

Withdrawn

Conditions: Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8
Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8
Resectable Mass
Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8
Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Pathologic Stage III Esophageal Adenocarcinoma AJCC v8

Interventions: Dietary Supplement: Nutritional Supplementation
Dietary Supplement: Nutritional Supplement Drink

First Posted Date: 2019-07-23

Last Posted Date: 2024-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04029857

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Phase 1

Withdrawn

Conditions: CD22 Positive
Progressive Disease
Refractory Chronic Lymphocytic Leukemia
Recurrent Non-Hodgkin Lymphoma
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Refractory Non-Hodgkin Lymphoma
CD19 Positive
Minimal Residual Disease

Interventions: Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2019-07-23

Last Posted Date: 2023-08-21

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04029038

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Phase 1

Recruiting

Conditions: Hematopoietic and Lymphoid System Neoplasm

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Bendamustine
Drug: Cyclophosphamide
Biological: Filgrastim-sndz
Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Rituximab
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2019-07-17

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT04022239

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

Not Applicable

Completed

Conditions: Invasive Breast Carcinoma
Recurrent Breast Carcinoma
Breast Carcinoma
Breast Ductal Carcinoma In Situ

Interventions: Other: Best Practice
Other: Medical Chart Review
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Supportive Care

First Posted Date: 2019-07-17

Last Posted Date: 2023-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 287

Registration Number: NCT04022772

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myeloproliferative Neoplasm
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myelodysplastic/Myeloproliferative Neoplasm

Interventions: Drug: Azacitidine
Drug: BRD4 Inhibitor PLX51107

First Posted Date: 2019-07-17

Last Posted Date: 2022-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT04022785

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients with Advanced Liver Cancer

Not Applicable

Recruiting

Conditions: Advanced Adult Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma AJCC V8
Stage IIIA Hepatocellular Carcinoma AJCC V8
Stage IIIB Hepatocellular Carcinoma AJCC V8
Stage IV Hepatocellular Carcinoma AJCC V8
Stage IVA Hepatocellular Carcinoma AJCC V8
Stage IVB Hepatocellular Carcinoma AJCC V8

Interventions: Procedure: Magnetic Resonance Elastography
Procedure: Magnetic Resonance Imaging

First Posted Date: 2019-07-17

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT04022746

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Phase 1

Active, not recruiting

Conditions: Metastatic Carcinoma in the Lung
Metastatic Malignant Neoplasm in the Thoracic Cavity
Advanced Malignant Solid Neoplasm
Metastatic Carcinoma in the Liver
Metastatic Malignant Solid Neoplasm

Interventions: Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156
Biological: Ipilimumab
Biological: Nivolumab
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2019-07-16

Last Posted Date: 2024-07-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT04021043

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy